Literature DB >> 10769274

The value of magnetic resonance imaging of the left ventricular outflow tract in patients with hypertrophic obstructive cardiomyopathy after septal artery embolization.

J Schulz-Menger1, O Strohm, J Waigand, F Uhlich, R Dietz, M G Friedrich.   

Abstract

BACKGROUND: We tested the value of magnetic resonance imaging (MRI) in the follow-up of patients with hypertrophic obstructive cardiomyopathy after septal artery embolization. MRI provides a noninvasive visualization of transplanar turbulent flow in order to quantify left ventricular outflow tract obstruction. METHODS AND
RESULTS: We followed 10 patients who were treated with septal artery embolization for 12 months. We used gradient echo sequences to document continuous improvement of the outflow tract area and T1- and T2-weighted spin echo sequences to visualize myocardial infarction. A continuous, but not linear, improvement of the outflow tract area occurred after septal artery embolization during the 12-month follow-up period. The improvement of the outflow tract area correlated well with the amelioration of symptoms (r(2)=0.86).
CONCLUSIONS: We conclude that MRI reliably detects the degree of obstruction in patients with hypertrophic obstructive cardiomyopathy. This modality may be especially useful for follow-up after septal artery embolization.

Entities:  

Mesh:

Year:  2000        PMID: 10769274     DOI: 10.1161/01.cir.101.15.1764

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  10 in total

1.  Increasing evidence for the safety and efficacy of alcohol septal ablation during medium- and long-term follow-up.

Authors:  M Pauschinger; A Keren
Journal:  Clin Res Cardiol       Date:  2007-11-05       Impact factor: 5.460

Review 2.  The emerging clinical role of cardiovascular magnetic resonance imaging.

Authors:  Andreas Kumar; David J Patton; Matthias G Friedrich
Journal:  Can J Cardiol       Date:  2010 Jun-Jul       Impact factor: 5.223

Review 3.  [Hypertrophic and restrictive cardiomyopathy. Differentiation by imaging].

Authors:  S Fritschi; M Prothmann; J Schulz-Menger
Journal:  Herz       Date:  2015-06       Impact factor: 1.443

4.  Cardiac magnetic resonance in hypertrophic cardiomyopathy.

Authors:  Milind Y Desai; Ashwat Dhillon; Andrew C Y To
Journal:  Curr Cardiol Rep       Date:  2011-02       Impact factor: 2.931

5.  Upregulation of rat P23 (a member of the YjgF protein family) by fasting, glucose diet and fatty acid feeding.

Authors:  F Levy-Favatier; A Leroux; B Antoine; B Nedelec; M Delpech
Journal:  Cell Mol Life Sci       Date:  2004-11       Impact factor: 9.261

6.  Rapid fatty acid ethyl ester synthesis by porcine myocardium upon ethanol infusion into the left anterior descending coronary artery.

Authors:  Danita M Yoerger; Catherine A Best; Brendan M McQuillan; Gregory E Supple; J Luis Guererro; Joanne E Cluette-Brown; Ali Hasaba; Michael H Picard; James R Stone; Michael Laposata
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

7.  Long-term follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy.

Authors:  H Seggewiss; A Rigopoulos; D Welge; P Ziemssen; L Faber
Journal:  Clin Res Cardiol       Date:  2007-09-27       Impact factor: 5.460

Review 8.  The "1st septal unit" in hypertrophic obstructive cardiomyopathy: a newly recognized anatomo-functional entity, identified during recent alcohol septal ablation experience.

Authors:  Paolo Angelini
Journal:  Tex Heart Inst J       Date:  2007

Review 9.  [Clinical picture and therapy of hypertrophic cardiomyopathy].

Authors:  U Gleichmann; H Seggewiss
Journal:  Med Klin (Munich)       Date:  1998-04-15

Review 10.  SCMR Position Paper (2020) on clinical indications for cardiovascular magnetic resonance.

Authors:  Tim Leiner; Jan Bogaert; Matthias G Friedrich; Raad Mohiaddin; Vivek Muthurangu; Saul Myerson; Andrew J Powell; Subha V Raman; Dudley J Pennell
Journal:  J Cardiovasc Magn Reson       Date:  2020-11-09       Impact factor: 5.364

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.